The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study (CTONG0803) of erlotinib as second-line treatment in advanced non-small cell lung cancer (NSCLC) patients (pts) with asymptomatic brain metastases (BM) after first-line chemotherapy (CT).
Y. L. Wu
Honoraria - AstraZeneca; Lilly; Pfizer; Roche
C. Zhou
No relevant relationships to disclose
Y. Cheng
No relevant relationships to disclose
S. Lu
No relevant relationships to disclose
G. Chen
No relevant relationships to disclose
C. Huang
No relevant relationships to disclose
Y. Huang
No relevant relationships to disclose
H. h. Yan
No relevant relationships to disclose
J. Yang
No relevant relationships to disclose